Sugi Predict

Sugi Predict / Compounds / SCHEMBL17341985

SCHEMBL17341985

SCHEMBL17341985

CC(C)COc1ccc(C(N)=O)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 10/20 0.65
▸ PARP4 Q9UKK3 2/20 0.55
▸ PARP2 Q9UGN5 2/20 0.55
▸ CA1 P00915 1/20 0.55
▸ CA2 P00918 1/20 0.55
▸ PARP1 P09874 1/20 0.55
▸ PARP15 Q460N3 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ PARP14 Q460N5 1/20 0.53
▸ PARP16 Q8N5Y8 1/20 0.53
▸ PARP11 Q9NR21 1/20 0.53
▸ MAPT P10636 3/20 0.53
▸ POLB P06746 2/20 0.53
▸ HPGD P15428 1/20 0.53
▸ XBP1 P17861 1/20 0.53
▸ NR1H4 Q96RI1 2/20 0.52
▸ DPP4 P27487 1/20 0.52
▸ NPSR1 Q6W5P4 2/20 0.51
▸ LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29245573 0.98 PARP10 (0.62) PARP10PARP4PARP2CA1CA2
SCHEMBL30151821 0.87 PARP10 (0.62) PARP10PARP4PARP2CA1CA2
SCHEMBL10609453 0.87 PARP10 (0.62) PARP10PARP4PARP2CA1CA2
SCHEMBL30151899 0.86 PARP10 (0.61) PARP10PARP4PARP2CA1CA2
SCHEMBL20665416 0.86 PARP10 (0.61) PARP10PARP4PARP2CA1CA2
SCHEMBL16109076 0.85 MAPT (0.56) ALDH1A1KMT2AMAPTPOLBHPGD
SCHEMBL27911613 0.85 FOS (0.61) ALDH1A1KMT2AMAPTPOLBHPGD
SCHEMBL834902 0.83 NR1H4 (0.70) CA1CA2KMT2AMAPTPOLB
SCHEMBL3010302 0.83 MAPT (0.73) ALDH1A1MAPTPOLBHPGDXBP1
SCHEMBL17340939 0.83 PARP10 (0.57) PARP10PARP4PARP2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118515606-A Tartaric acid pima method for synthesizing tryptamine 江苏宇锐医药科技有限公司 2024-08-20 — — CN claimed
CN-110156664-B Method for synthesizing pimavanserin 常州大学 2022-03-01 — — CN claimed
CN-110156664-A A kind of synthetic method of piperazine Ma Selin 常州大学 2019-08-23 — — CN claimed
CN-118515606-A Tartaric acid pima method for synthesizing tryptamine 江苏宇锐医药科技有限公司 2024-08-20 — — CN disclosed
CN-118515606-A Tartaric acid pima method for synthesizing tryptamine 江苏宇锐医药科技有限公司 2024-08-20 — — CN disclosed
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 — — US disclosed
CN-110156664-B Method for synthesizing pimavanserin 常州大学 2022-03-01 — — CN disclosed
EP-3394056-B1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2021-04-14 — — EP disclosed
EP-3271018-B1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN PLIVA HRVATSKA D O O (HR) 2020-12-23 — — EP disclosed
US-10807953-B2 Processes and intermediates for the preparation of Pimavanserin PLIVA HRVATSKA D.O.O. (HR) 2020-10-20 — — US disclosed
US-20190276401-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN PLIVA HRVATSKA D.O.O. (HR) 2019-09-12 — — US disclosed
CN-108395384-A The green synthesis method of isocyanates 辽宁科技学院 2018-08-14 — — CN disclosed
US-20180037549-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN TAPI CROATIA INDUSTRIES LTD (HR) 2018-02-08 — — US disclosed
US-20180037549-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN TAPI CROATIA INDUSTRIES LTD (HR) 2018-02-08 — — US disclosed
WO-2017112777-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2017-06-29 — — WO disclosed
EP-2847174-B1 PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2017-05-17 — — EP disclosed
US-9394260-B2 Pyrimidinone carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2016-07-19 — — US disclosed
US-20150361052-A1 PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY 2015-12-17 — — US disclosed
CN-102276550-B The synthetic method of 2-aryl nitrile thiazole derivative and intermediate thereof JIUZHOU PHARMACEUTICAL CO., LTD., ZHEJIANG (CN) 2015-08-19 — — CN disclosed
CN-102276550-A Method for synthesizing 2-aryl nitrile thiazole derivative and intermediate thereof — 2011-12-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS MAPT, HTT, PSEN1 PARP10 396/4885PARP4 201/4885PARP2 63/4885
US-10807953-B2 Processes and intermediates for the preparation of Pimavanserin PIM1, PIM3, PIM2 PARP10 395/4885PARP4 499/4885PARP2 704/4885
US-20150361052-A1 PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, LPL, PNLIP PARP10 1274/4885PARP4 1131/4885PARP2 1139/4885
US-20190276401-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN PIM1, PIM3, PIM2 PARP10 395/4885PARP4 499/4885PARP2 704/4885
US-20180037549-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN PIM1, PIM3, PIM2 PARP10 395/4885PARP4 499/4885PARP2 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.